PF-06648671

Cat. No.:	HY-120789
CAS No.:	1587727-31-8
Molecular Formula:	$C_{25}H_{23}ClF_4N_4O_3$
Molecular Weight:	538.92
Target:	γ-secretase
Pathway:	Neuronal Signaling; Stem Cell/Wnt
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	PF-06648671 is a novel, brain‐penetrable, and orally active γ‐secretase modulator (GSM). PF-06648671 reduces Aβ42 and A β40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer's disease[1].
IC_{50} & Target	IC50: γ‐secretase[1]
In Vitro	In a cell‐based assay, PF‐06648671 reduces Aβ42 and Aβ40 , with concomitant increases in Aβ37 and Aβ38, without inhibiting the cleavage of Notch or other substrates[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	PF‐06648671 demonstrates reduces Aβ42 within the brain and CSF following acute oral administration in animals[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jae Eun Ahn, et al. Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies. Clin Pharmacol Ther 2020 Jan;107(1):211-220.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA